Gene News and Research

Latest Gene News and Research

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Scientists identify and prioritize genes associated with schizophrenia

An Indiana University-led research team, along with a group of national and international collaborators, has identified and prioritized a comprehensive group of genes most associated with schizophrenia that together can generate a score indicating whether an individual is at higher or lower risk of developing the disease.

16 May 2012

Genetic factor for good memory may increase risk of PTSD in war victims

Experiencing distressing memories of a shocking experience characterizes posttraumatic stress disorder. Scientists from the University of Basel have now discovered that a genetic factor for good memory is also associated with a heightened risk for the development of a posttraumatic stress disorder in war victims.

16 May 2012

Intriguing links between Snf2l gene and brain developmental disorders

Scientists at the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) have discovered that mice that lack a gene called Snf2l have brains that are 35 per cent larger than normal.

16 May 2012

Two specific gene variants speed progression of Parkinson's disease

UCLA researchers may have found a key to determining which Parkinson's disease patients will experience a more rapid decline in motor function, sparking hopes for the development of new therapies and helping identify those who could benefit most from early intervention.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Mass. Eye and Ear announces recipients of 2012 Curing Kids Fund grants

The Mass. Eye and Ear Curing Kids fund has awarded grants for research projects that aim to help the brain locate sound, identify genes that cause congenital blindness, cure deafness through hair cell regeneration, and improve treatment for childhood eye cancer.

16 May 2012

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals, relaying thoughts, feelings and action, and this powerful molecule plays a crucial role in regulating effective communication.

15 May 2012

Study identifies biomarkers that can predict recurrence of prostate cancer

Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found.

15 May 2012

Paediatric brain tumours preserve specific characteristics of normal cells from which they originate

Paediatric brain tumours preserve specific characteristics of the normal cells from which they originate - a previously unknown circumstance with ramifications for how tumour cells respond to treatment.

15 May 2012

Genetic test can accurately predict spread of eye cancer

Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver.

15 May 2012

Researchers identify new biomarker and therapeutic target for pancreatic cancer

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.

15 May 2012

Study identifies how skeletal muscle stem cells respond to muscle injury

A study conducted by Children's Hospital & Research Center Oakland scientists identifies how skeletal muscle stem cells respond to muscle injury and may be stimulated to improve muscle repair in Duchenne Muscular Dystrophy, a severe inherited disease of muscle that causes weakness, disability and, ultimately, heart and respiratory failure.

15 May 2012

MicroRNA-3151 a new independent prognostic marker for acute leukemia

A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes.

15 May 2012

Groundbreaking biohybrid device to control acute inflammation to prevent sepsis

The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.

14 May 2012

Genetic cause of rare genetic disorder, Hamamy syndrome

Scientists at A*STAR's Institute of Medical Biology (IMB), in collaboration with doctors and scientists in Jordan, Turkey, Switzerland and USA, have identified the genetic cause of a birth defect known as Hamamy syndrome .

14 May 2012

Regenerating sensory hair cells could help treat hearing loss

Regenerating sensory hair cells, which produce electrical signals in response to vibrations within the inner ear, could form the basis for treating age- or trauma-related hearing loss. One way to do this could be with gene therapy that drives new sensory hair cells to grow.

14 May 2012

Lung cancer molecular subtypes correlate with genetic alterations, patient's response to therapy

Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient's individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient's response to therapy.

14 May 2012

Study describes new compounds that inhibit PRMT1 enzyme

Scientists at The Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.

11 May 2012

Study reveals sex-specific fitness benefit of variability of MHC genes

Females of mammals (including humans) tend to outlive males, a circumstance that is usually attributed to males- more aggressive and hence energy-depleting behaviour, especially when they compete for females. This might also explain why males of many species usually show a higher parasite burden than females.

11 May 2012